explore -WSS

explore

author：hotspot 2025-09-28 01:31:52 - browse：912

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： A protest over insulin prices is seen as a fight for life

WSS

Why more medical students aren't specializing in primary care

Apellis safety probe of eye disease drug centers on injection needle

As pharma fights Medicare drug negotiation, hospitals, docs silent

Surgery pushed Ben Carson to fame

Departing Stanford president retracts two papers

Texas Medical Board asked to define abortion emergency exception

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

In age of alternative facts, a scholarly course on calling out crap

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Activists slam private health insurers over coverage restrictions

Medicare explains how it will choose drugs for negotiation

The high cost of giving birth even with insurance

Neuroscience startup Neumora files for IPO

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to make AI work for medicine

Heart attack and stroke risk calculators need revising

Johnson & Johnson sued for allegedly overpaying for workers' drugs

entertainment

CDC advisory panel says seniors 'may' get RSV vaccine

Apellis safety probe of eye disease drug centers on injection needle

A single Democrat is willing to weaken Medicare negotiation power

Cano Health’s bankruptcy is a warning for Medicare Advantage

AstraZeneca bets AAV gene therapy will still deliver the goods

A protest over insulin prices is seen as a fight for life

focus

entertainment

hotspot

focus